MAP2K5 and non-small cell lung carcinoma: As a critical driver of glutamine metabolic reprogramming, FGF17—activated under conditions of GLUL overexpression—stimulates the FGFR4/MEK5/ERK5/NRF2 signaling cascade to maintain redox homeostasis and promote invasion, thereby accelerating NSCLC progression.